

Swiss Recommendations for the Follow-Up and Treatment of Pulmonary Long COVID.

Title: Swiss Recommendations for the Follow-Up and Treatment of Pulmonary Long COVID.

Publication year: 2021

Journal: Respiration; international review of thoracic diseases

Authors: Department for Pulmonary Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.

Society: European Respiratory Society

Origin country: International (Europe)

Target countries: Europe

DOI: 10.1159/000517255

PMID: 34091456

Source: <https://pubmed.ncbi.nlm.nih.gov/34091456/>

pmc Respiration Respiration 2985 kargersd 0137356 RES Respiration 0025-7931 1423-0356
pmc-is-collection-domain yes pmc-collection-title Karger Author's Choice PMC8339046
PMC8339046.2 8339046 8491465 34091456 10.1159/000517255 res-0100-0826 2 Guidelines
Swiss Recommendations for the Follow-Up and Treatment of Pulmonary Long COVID
Funke-Chambour Manuela a b * Bridevaux Pierre-Olivier c d Clarenbach Christian F. e Soccal
Paola M. d f Nicod Laurent P. g h von Garnier Christophe h a Department for Pulmonary Medicine,
Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland b Department for
Pulmonary Medicine, BioMedical Research, University of Bern, Bern, Switzerland c Service de
Pneumologie, Hôpital du Valais, Sion, Switzerland d Geneva Medical School, University of Geneva,
Geneva, Switzerland e Department of Pulmonology, University Hospital Zurich, Zurich, Switzerland
f Division of Pulmonary Medicine, Geneva University Hospitals, Geneva, Switzerland g Pulmonary
Medicine, Clinique Cecil du groupe Hirslanden, Lausanne, Switzerland h Division of Pulmonary
Medicine, Lausanne University Hospital (CHUV), University of Lausanne, Lausanne, Switzerland
*Manuela Funke-Chambour, manuela.funke-chambour@insel.ch 8 2021 4 6 2021 100 8 391322
826 841 27 4 2021 29 4 2021 2021 04 06 2021 05 08 2021 14 08 2025 8339046
10.1159/000517255 1 04 06 2021 8491465 10.1159/000517255 2 04 06 2021 Copyright © 2021 by
S. Karger AG, Basel 2021 Introduction Emerging evidence suggests that long-term pulmonary
symptoms and functional impairment occurs in a proportion of individuals following SARS-CoV-2
infection. Although the proportion of affected patients remains to be determined, physicians are
increasingly being confronted with patients reporting respiratory symptoms and impairment beyond
the acute phase of COVID-19. In face of limited evidence, the Swiss Society for Pulmonology
established a working group to address this area of unmet need and formulated diagnostic and
treatment recommendations for the care of patients with pulmonary long COVID (LC).

The Swiss COVID Lung Study group and Swiss Society for Pulmonology (SSP) formulated 13
questions addressing the diagnosis and treatment of pulmonary LC. A survey within the SSP
special interest groups involved in care of LC patients was conducted in Switzerland. A CORE
process/Delphi-like process was used to formulate recommendations. Forty experienced
pulmonologists replied to the first survey and 22 completed the second follow-up survey.
Agreement of $\geq 70\%$ consensus led to formulation of a recommendation.

The participants in the survey reached consensus and formulated a strong recommendation for
regarding the following points. Patients hospitalized for COVID-19 should have a pulmonary
assessment including pulmonary function tests. Symptomatic subjects affected by COVID-19,
including those with mild disease, should benefit from a pulmonary follow-up. Persistent respiratory
symptoms after COVID-19 should be investigated by a pulmonary follow-up including
plethysmography, diffusion capacity measurement, and blood gases analysis. Individuals having
suffered from COVID-19 and who present with persistent respiratory symptoms should be offered a
rehabilitation. Additional questions were given moderate or weak recommendations for . The panel

did not reach sufficient consensus for pharmacological therapy (e.g., therapy specifically targeting lung fibrosis) to formulate recommendations for LC drug treatment.

The formulated recommendations should serve as an interim guidance to facilitate diagnosis and treatment of patients with pulmonary LC. As new evidence emerges, these recommendations may need to be adapted.

pmc-status-qastatus 0 pmc-status-live yes pmc-status-embargo no pmc-status-released yes
pmc-prop-open-access yes pmc-prop-olf no pmc-prop-manuscript no pmc-prop-legally-suppressed
no pmc-prop-has-pdf no pmc-prop-has-supplement yes pmc-prop-pdf-only no
pmc-prop-suppress-copyright no pmc-prop-is-real-version no pmc-prop-is-scanned-article no
pmc-prop-preprint no pmc-prop-in-epmc yes Summary of Recommendations Question 1: Should All
Patients Hospitalized for COVID-19 Have a Pulmonary Follow-Up? All patients hospitalized for
COVID-19 should have a pulmonary follow-up. (strong recommendation for, consensus reached)

The suggested time frame is within 3 months after infection. (suggestion, no consensus)

All COVID-19 affected patients, including those with mild disease, should have a pulmonary follow-up, if symptomatic. (strong recommendation for, consensus reached)

The suggested time frame is within 3 months after infection. (suggestion, no consensus)

All patients with persistent respiratory symptoms after COVID-19 should have a pulmonary follow-up including plethysmography, diffusion capacity measurement, and blood gases analysis. (strong recommendation for, consensus reached)

For patients with severe COVID-19 (WHO definition), a pulmonary follow-up is recommended including plethysmography and diffusion capacity, blood gases analysis independently of symptom persistence. (moderate recommendation for, consensus reached when strong and weak recommendations are merged)

Remark: Consensus was reached when strong and weak recommendations are merged, 64% gave a strong recommendation for and 36% a weak recommendation for.

Exercise testing (e.g., 6MWD or equivalent) is recommended after COVID-19. (weak recommendation for, consensus reached)

Chest CT scan is recommended to be routinely performed in patients with persisting respiratory symptoms after COVID-19. (moderate recommendation for, consensus reached when strong and weak recommendations are merged)

Remark: Consensus was reached when strong and weak recommendations are merged, 68% gave a strong recommendation for and 32% a weak recommendation for.

Cardio-pulmonary exercise test (CPET) is recommended to be routinely performed after COVID-19 with persistent symptoms. (moderate recommendation for, consensus reached when strong and weak recommendations are merged)

Remark: Consensus was reached when strong and weak recommendations are merged, 14% gave a strong recommendation for and 68% a weak recommendation for.

Patients with persistent symptoms after COVID-19 are recommended to have access to specialized multidisciplinary Post-COVID-19 clinics or networks. (moderate recommendation for, consensus reached when strong and weak recommendations are merged)

Remark: Consensus was reached when strong and weak recommendations are merged, 55% gave a strong recommendation for and 41% a weak recommendation for.

Patients after COVID-19 who present with new obstructive lung disease are recommended to be offered empiric topic inhaled or systemic steroid treatment. (moderate recommendation for, consensus reached when strong and weak recommendations are merged)

Remark: Consensus was reached when strong and weak recommendations are merged, 36% gave a strong recommendation for and 36% a weak recommendation for.

Patients after COVID-19 who present with persistent cough are recommended to have empiric inhaled topic steroids. (moderate recommendation for, consensus reached when strong and weak recommendations are merged)

Remark: Consensus was reached when strong and weak recommendations are merged, 32% gave a strong recommendation for and 45% a weak recommendation for.

Patients after COVID-19 who present with interstitial abnormalities after exclusion of an active infection are recommended to be evaluated to receive an empiric systemic steroid trial. (moderate recommendation for, consensus reached when strong and weak recommendations are merged)

Remark: Consensus was reached when strong and weak recommendations are merged, 14% gave a strong recommendation for and 59% a weak recommendation for.

It is unclear whether patients after COVID-19 who present with signs of pulmonary fibrosis should receive specific antifibrotic drugs. (suggestion for no recommendation, no consensus)

Patients after COVID-19 who present with persistent respiratory symptoms are recommended to undergo a rehabilitation program. (strong recommendation for, consensus reached)

Previous Coronavirus infections, including Severe Acute Respiratory Syndrome (SARS) [1] and Middle East respiratory syndrome (MERS), [2] were associated with a high mortality, pulmonary complications including acute respiratory distress syndrome (ARDS), and long-term sequelae in survivors [3 , 4]. COVID-19 caused by SARS-CoV2, has a similar initial clinical presentation as SARS and MERS. Initial symptoms include fever, cough and dyspnea, and bilateral opacities may be observed radiologically. ARDS is also a major respiratory complication in COVID-19, particularly in elderly patients [5 , 6]. ARDS itself can result in pulmonary sequelae and long-term impairment [7]. Whether pulmonary sequelae after coronavirus infections are linked to ARDS [7] or are related to virus-specific mechanisms of disease remains to be clarified [8 , 9].

Cumulative literature addresses persisting pulmonary and extrapulmonary symptoms after acute COVID-19 infection [10 , 11]. These symptoms and associated organ manifestations are increasingly referred to as long COVID (LC) syndrome, although a universal definition is still missing. The post-acute COVID-19 period is considered in the presence of symptoms up to 3 weeks after infection, while LC persists beyond 12 weeks after infection [12 , 13].

The characteristics and time-points of LC manifestations vary between 3 and 12 weeks after acute infection [12 , 13]. Persistence of symptoms that last more than 2 or 3 months beyond the COVID-19 infection without alternative diagnosis have been described [14 , 15]. A modified proposal for a definition according to these recent publications is shown in Table 1 . The causes for symptom persistence and organ impairment are unknown, but hypotheses range from immunological phenomena, persistent subclinical virus infection, post-ICU syndrome to diffuse thrombotic damage due to endotheliitis [13 , 16].

Long COVID-19 treatment programs and multidisciplinary/interdisciplinary LC consultations are increasingly being set up [17]. Although calls are made and efforts initiated to formulate guidance for physicians for treating patients with persistent symptoms or LC [18 , 19], scientific evidence to support clinically meaningful guidelines is sparse. Switzerland has been one of the first European countries affected by the ongoing pandemic of COVID-19 in spring 2020. Persistence of respiratory symptoms 4 months after the infection has been investigated within a Swiss wide national observational study for lung sequelae (Swiss COVID Lung Study: NCT04581135), showing that respiratory impairment is most pronounced in patients following severe disease [20]. Diagnostic and treatment approaches of patients after COVID-19 have not been defined yet.

The Swiss COVID Lung Study group and SSP have conducted a survey within its special interest group (SIG) involved in care of COVID-19 patients to evaluate interim recommendations by its members for treatment of individuals with LC. Members of the SSP SIG Sleep Breathing Disorders, Prevention (tobacco/environment), Pulmonary Vascular Disease, Obstructive Lung Diseases & Allergy, Thoracic Interventions & Oncology, Infections, Tuberculosis, CF/non-CF Bronchiectasis, Functional Diagnostics and Sports Pulmonology, Interstitial and Rare Lung Diseases and Ventilation and O 2 participated in the survey, and names of participants are listed in the Acknowledgements.

In absence of clinical evidence, the Convergence of Opinion on Recommendations and Evidence (CORE) process/Delphi-like process is an adequate tool to formulate recommendations for physicians that need to be adapted before evidence accumulates and international consensus becomes available [21]. Questions were formulated with PICO (Population, Intervention, Comparison, and Outcome) format by an expert core committee listed as authors. The questions were discussed in a video conference on January 25th, 2021 by the participants to ensure that they accurately conveyed their intent, were clearly written, and all terms have been defined. Due to the current pandemic with restricted possibilities for face-to-face exchange, subsequent discussions were conducted virtually or by email exchange.

The electronic survey was conducted by LamaPoll® sent to all members of the SSP SIGs listed above. For each question, the respondent had to choose among a strong or weak recommendation for or against the course of action or no recommendation; participants also had the opportunity to provide written comments.

A second survey was subsequently issued that was identical to the first, with the exception that numerical responses and comments from the first survey were provided.

Agreement of $\geq 70\%$ consensus led to formulation of a recommendation. If consensus could not be reached, no recommendation was provided, but a suggestion was formulated, if possible. If a majority of the survey participants decided for a strong or weak recommendation ($\geq 70\%$ if combined), consensus for a recommendation for was assumed and a moderate recommendation was provided.

The committee held another videoconference to discuss the survey results on March 31st, 2021. The summary and conclusions of this discussion were integrated into the manuscript.

A total of 40 pulmonologists from all parts of Switzerland responded to the first and 22 participated in the second survey. Most pulmonologist had extensive experience with acute COVID-19 patients (42% in the first and 55% in the second survey with >50 acute COVID-19 patients). More than 56% (68% in the second survey) treated up to 50 LC patients at the time of the survey, while only 14% were in charge of more than 50 LC patients in both surveys. This discrepancy between acute and LC care may be related to the time point of the survey before the end of the second wave in February 2021. As experience with LC was more extensive in the second survey and probably physicians with specific interest in pulmonary LC replied the second round, the results of the second survey were used to define consensus for recommendations.

An overview of the recommendations and suggestions is provided in a summarized form including individual survey results in Table 2 .

Most patients hospitalized for COVID-19 pneumonia have persistent symptoms after 3–4 months [22]. Forty-two percent of these patients report dyspnea, indicating persistent pulmonary impairment after acute infection [22]. In a Norwegian study 3 months after COVID-19, symptoms persisted in half of the patients with one-quarter having reduced diffusion capacity [23]. These findings were also confirmed by an Austrian study group [24]. In a Swiss study, specifically those with ARDS showed lung functional impairment with mainly reduced diffusion capacity 4 months after acute infection [20]. After severe COVID-19, lung functional abnormalities with impaired diffusion capacity persisted until 6 months in a recent publication [25]. Pulmonary follow-up was already suggested early in the pandemic before evidence for pulmonary sequelae emerged [26]. National German S3 Recommendations for treatment of hospitalized COVID patients suggest a clinical follow-up after 8–12 weeks to detect long-term sequelae, if possible within a study or registry [27].

The committee discussed the need for a pulmonary follow-up in patients after hospitalization. There was agreement within the committee that a pulmonary follow-up in patients after hospitalization with COVID-19 is useful and should be performed within 3 months after initial symptoms.

A post-COVID-19 pulmonary follow-up includes, but is not limited to, specific assessment of respiratory complaints and history of COVID-19, physical examination and appropriate lung function exploration. The pulmonary follow-up can be backed by specific and generic quality of life questionnaires, specific laboratory investigations (e.g., SARS-CoV2 antibody confirmation), and imaging studies.

All patients hospitalized for COVID-19 should have a pulmonary follow-up. (strong recommendation for, consensus reached)

The suggested time frame is within 3 months after infection. (suggestion, no consensus)

Remarks for Question 1: Should all patients hospitalized for COVID-19 have a pulmonary follow-up? 70% (second survey: 77%) strong recommendation for, 26% (second survey: 18%) weak recommendation for, 0% (second survey: 0%) strong recommendation against, 5% (second survey: 5%) weak recommendation against, 0% (second survey: 0%) no recommendation.

Remarks for additional question: At what time point should respiratory tests be performed? 20% (second survey: 10%) after 1 month, 17% (second survey: 14%) after 2 months, 49% (second survey: 62%) after 3 months, 2% (second survey: 0%) after 4 months, 12% (second survey: 14%) gave no recommendation.

A recent study showed that in patients who did not require hospitalization for COVID-19 pneumonia, about half remained symptomatic after 2 months and had lung functional abnormalities [28]. As most other studies and current data focus on hospitalized patients, it is difficult to evaluate lung functional impairment in patients with mild disease courses. Nevertheless, symptomatic patients might benefit from exclusion of treatable causes of dyspnea.

The committee discussed the necessity to further investigate patients with persisting respiratory symptoms. These investigations should take place within 3 months after symptoms of acute COVID-19.

All COVID-19 affected patients, including those with mild disease, should have a pulmonary follow-up if symptomatic. (strong recommendation for, consensus reached)

The suggested time frame is within 3 months after infection. (suggestion, no consensus)

Remarks for Question 2: Should all COVID-19 affected patients including those with mild disease have a pulmonary follow-up if symptomatic? 74% (second survey: 82%) strong recommendation for, 23% (second survey: 14%) weak recommendation for, 2% (second survey: 0%) strong recommendation against, 0% (second survey: 0%) weak recommendation against, 0% (second survey: 5%) no recommendation.

Remarks for additional question: At what time point should respiratory tests be performed? 24% (second survey: 5%) after 1 month, 12% (second survey: 10%) after 2 months, 48% (second survey: 62%) after 3 months, 5% (second survey: 0%) after 4 months, 12% (second survey: 24%) gave no recommendation.

Since the beginning of the SARS-CoV2 pandemic, several cohort studies examining pulmonary function tests (PFTs) at various time points have been conducted. Included patients were mostly admitted with severe or moderate disease. The vast majority was on oxygen therapy, noninvasive ventilation, high flow nasal cannula or mechanical ventilation during the acute phase of the COVID-19. PFTs were assessed at discharge, 30 days, 4 months [29], and up to 6 months [25]. Overall, the carbon monoxide transfer capacity (TLCO) was uniformly reduced while forced vital capacity (FVC) and forced expiratory volume in 1 s (FEV1) were within normal range in most cases. Patients with more severe acute infection had lower TLCO value. FVC and total lung capacity (TLC) were reduced only in the patients with the most severe acute infection. Huang et al. [25] observed that 56% of the patients treated with mechanical ventilation had TLCO below 80% predicted after 6 months. Among those who received oxygen therapy or no oxygen, reduced TLCO was measured in 29 and 22%, respectively [25]. Obstructive patterns on spirometry were not observed in these studies.

What lessons can be learned from previous coronavirus epidemics? SARS-CoV-1 and Middle East respiratory syndrome (MERS) caused a long-term decline in lung function. Between 6 months and 2 years after infection with SARS-CoV-1, there was a decrease in TLCO and TLC (restrictive syndrome) in 15.5–43.6% and 5.2–10.9% of cases, respectively [3 , 4]. In survivors of MERS, TLCO was still reduced in 37% 12 months after acute infection [30].

Low TLCO in patients with LC is associated with interstitial infiltrates on chest CT scan. The available studies do not detail arterial blood gas analysis after acute COVID-19.

Evaluation of persistent respiratory symptoms is an indication to perform PFTs [31]. The panel specified that plethysmography should be performed on top of spirometry and diffusion capacity measurements if these are abnormal, to provide assessment of a possible restrictive ventilatory defect. The panel suggests performing arterial blood gas measurements in patients with low transcutaneous oxygen saturation at rest ($SpO_2 < 92\%$), desaturation on exercise ($SpO_2 < 90\%$), or receiving supplemental domiciliary oxygen therapy.

All patients with persistent respiratory symptoms after COVID-19 should have a pulmonary follow-up including plethysmography, diffusion capacity measurement and blood gases analysis. (strong recommendation for, consensus reached)

Remarks for Question 3: Should all patients with persistent respiratory symptoms after COVID-19 have a pulmonary follow-up including plethysmography, diffusion capacity measurement and blood gases analysis? 91% (second survey: 100%) strong recommendation for, 5% (second survey: 0%) weak recommendation for, 0% (second survey: 0%) strong recommendation against, 2% (second survey: 0%) weak recommendation against, 2% (second survey: 0%) no recommendation.

Early observations found impaired diffusion capacity in patients after COVID-19 hospital discharge [29], and half of patients had impaired lung function after 30 days [32]. Our recent study showed impaired oxygen uptake up to 4 months after severe or critical COVID-19 [20]. An overview about

current studies with lung functional measurements after severe disease is provided in online supplementary Table 1 (for all online suppl. material, see www.karger.com/doi/10.1159/000517255). Whether the reduced diffusion capacity is due to alveolar surface loss, interstitial fibrosis, or vascular impairment cannot be judged from this value alone [33 , 34 , 35]. Plethysmography is helpful to detect a restrictive ventilator defect, as observed in pulmonary fibrosis and described after COVID-19 [36]. Arterial blood gas analysis facilitates diagnosis of hypoxemia, which may be associated with impaired diffusion capacity.

Most data on lung functional impairment emerge from prospective research cohort COVID-19 follow-up studies. Recent publications indicate that pulmonary impairment is more prevalent after severe disease [20 , 25].

Assessment of disease impact is an additional indication to perform PFTs [31]. The committee agreed that a routine pulmonary follow-up is justified in those patients in which severe pulmonary sequelae are expected and that require evaluation for treatment.

For patients with severe COVID-19 (WHO definition), a pulmonary follow-up is recommended, including plethysmography and diffusion capacity, blood gases analysis independently of symptom persistence. (moderate recommendation for, consensus reached when strong and weak recommendations are merged)

Remarks for Question 4: Should all patients with severe COVID-19 (WHO definition) have a pulmonary follow-up including plethysmography and diffusion capacity, blood gases analysis independently of symptom persistence? 49% (second survey: 64%) strong recommendation for, 44% (second survey: 36%) weak recommendation for, 2% (second survey: 0%) strong recommendation against, 2% (second survey: 0%) weak recommendation against, 2% (second survey: 0%) no recommendation.

Increasing evidence suggests that a range of respiratory symptoms persists in a substantial number of COVID-19 survivors. Several studies suggest that these occur independently of the initial degree of severity of the disease [23 , 37 , 38]. Respiratory symptoms such as dyspnea occurred in up to 40% of individuals 2–6 months following COVID-19 [10 , 25]. Exercise testing is commonly performed to investigate respiratory impairment, and the straightforward 6 min walking test (6MWT) is a useful tool to evaluate a range of chronic respiratory conditions [39]. Although the 6MWT has not been validated in COVID-19-associated pulmonary impairment, it is being increasingly employed to evaluate individuals after COVID-19 to diagnose exercise-related hypoxia and evaluate decreased exercise capacity [23 , 25 , 40]. In a Norwegian single-center study, half of the patients had hypoxia ($\text{SpO}_2 < 90\%$) during the 6MWT before hospital discharge [41]. Another study that evaluated patients with severe disease after 6 weeks found that walking distances in the 6MWT were under the predicted value for 79% of the participants, albeit without desaturation [42]. Data from a Swiss observational study acquired 4 months following severe/critical COVID-19 also showed a decreased 6MWT distance, but with significant desaturation in such patients [20]. A Chinese study performed in 1,733 COVID-19 patients 6 months following COVID-19 observed that between 24–29% of patients had a 6MWT distance less than the lower normal range depending on the severity of the SARS-CoV-2 infection [25]. In addition, the 6MWT has been employed as a useful investigation to monitor COVID-19 patients during rehabilitation [43 , 44]. To date no guideline exists that recommends the 6MWT as a routine examination in patients following COVID-19.

The committee discussed that the form of exercise testing might depend on the local possibilities. A 6MWD should be performed as a minimum to detect exercise hypoxia in patients with otherwise normal lung functional testing. In case of suspected impaired oxygen uptake, CPET may be useful to determine the underlying pathology.

Exercise testing (e.g., 6MWD or equivalent) is recommended after COVID-19. (weak recommendation for, consensus reached)

Remarks for Question 5: Should exercise testing (e.g., 6MWD or equivalent) be routinely performed after COVID-19? 26% (second survey: 0%) strong recommendation for, 52% (second survey: 77%) weak recommendation for, 7% (second survey: 0%) strong recommendation against, 5% (second survey: 9%) weak recommendation against, 12% (second survey: 14%) no recommendation.

A range of radiological abnormalities have been reported following COVID-19 infection [45]. In addition to interstitial opacities, consolidations and pneumatoceles, air trapping suggestive of small airways disease and/or microvascular thrombosis has been described [45]. A 3 months' follow-up study from The Netherlands reported a reduction (but persistence) of ground-glass opacification (GGO), bronchi(ol)ectasis, lines or bands, and fibrotic changes in 86, 60, 64, and 26% of participants, respectively [46]. The presence of an increased number of such abnormalities was associated with lower diffusion capacity [46]. Specifically, radiological signs of fibrosis were associated with older age, decreased TLC, and oxygen desaturation in the 6MWT, but not dyspnea [46]. In a 4 months' follow-up, we found an association between mosaic hypo-attenuation and severe/critical COVID-19 that may indicate small airways involvement and/or microvascular sequelae [20]. Although consolidations, interstitial involvement with sub-pleural lines, and ground-glass opacities had mostly resolved by 5 months, a Chinese Study on 1,733 participants observed that extensive radiological abnormalities in CT scans were associated with more severe clinical courses of COVID-19 [25]. In addition, the authors reported an increased risk of diffusion impairment, depression, fatigue, and muscle weakness in the presence of more pronounced radiological abnormalities [25]. A 6 months' follow-up reported residual CT abnormalities in 62% of patients and fibrotic-like changes in one-third of patients with severe COVID-19 [47]. Such radiographic abnormalities were associated with older age, ARDS, extensive initial chest CT scan changes, and impaired diffusion capacity [47]. Importantly, 63% of patients with ARDS developed fibrotic-type changes after 6 months, compared to 5% in non-ARDS patients [47].

While all the above follow-up studies provide valuable information on chest CT scan abnormalities, important questions on the long-term clinical and histologic consequences remain unanswered to date: First, do fibrotic chest CT scan abnormalities reliably identify irreversible alterations after COVID-19-related ARDS? Second, what is the significance and outcome of other, nonfibrotic chest CT scan patterns such as GGOs that have been associated with irreversible ILD [48]. Finally, how do chest CT scan patterns in post-COVID-19 ARDS and ventilator-induced lung damage differ from those abnormalities related to inflammatory pathways caused by COVID-19 that may eventually progress to lung fibrosis in a small proportion of patients?

In summary, despite an increasing number of published long-term follow-up studies, the evidence for radiological patterns that enable prediction of a clinical course and/or prognosis after COVID-19 is still insufficient.

The committee agreed that, until further data is available, follow-up chest CT imaging should be performed in patients with unexplained respiratory symptoms and functional impairment after COVID-19. The protocol of the chest CT scan needs to be defined and is subject of current evaluations.

Chest CT scan is recommended to be routinely performed in patients with persisting respiratory symptoms after COVID-19. (moderate recommendation for, consensus reached when strong and weak recommendations are merged)

Remarks for Question 6: Should chest CT scan be routinely performed in patients with persisting respiratory symptoms after COVID-19? 40% (second survey: 68%) strong recommendation for, 42% (second survey: 32%) weak recommendation for, 2% (second survey: 0%) strong recommendation against, 7% (second survey: 0%) weak recommendation against, 9% (second

survey: 0%) no recommendation.

To date few observational studies addressed this question [11]. When addressing this question in July 2020, the ATS/ERS international task force provided no recommendation for or against routine cardio-pulmonary exercise testing, within 30–60 days post-COVID-19 pneumonia [19]. Despite an agreement that CPET would be useful for the follow-up of the patients, concerns were raised regarding the potential risks of exposing health-care workers to aerosols in case of undiagnosed COVID-19 infection. This concern does not apply to LC patients who are not carriers of an active infection. It has to be stressed that the task force was concerned exclusively about routine testing, and it recommended a case-by-case evaluation for symptomatic patients (either new or persistent symptoms). Using a 1 min sit-to-stand test, the Short Physical Performance Battery (to assess lower extremities function) and the Barthel index (to assess performance for activities of daily life), Belli et al. [49] reported in a small retrospective study, abnormal physical and functioning performances in 30–50% of 103 COVID-19 patients who survived hospitalization, at discharge, highlighting the need to establish an objective reference baseline, e.g. by CPET, from which to monitor recovery over time. In a letter to the editor, Gao et al. [50] reported the CPET results performed in 10 rehabilitated patients with COVID-19, one month post-discharge, having observed reduced peak VO₂ in all cases and decreased oxygen pulse in a vast majority. More recently, a small retrospective German study reported CPET results obtained by testing 10 patients with persistent post-COVID-19 dyspnea. They found a reduced mean peak oxygen uptake at 73% of predicted value, a preserved mean peak work rate (92.4% of predicted value) and a high mean value of lactate, supporting the hypothesis that post-COVID-19 dyspnea may be mostly related to muscular limitation [51]. In conclusion, there are currently no RCTs or prospective studies with sufficient numbers of patients to draw sound conclusions regarding the question of the indication to perform a routine CPET for patients with persistent symptoms after COVID-19.

The feasibility to perform routine CPET is limited in several centers. If available, the committee stresses the usefulness of CPET if unexplained gas exchange impairment is present. CPET is also helpful to determine work inability in patients with reduced physical exercise capacity. It has to be stated that the second survey was very close to reaching a consensus for a weak recommendation for performing routine CPET.

CPET is recommended to be routinely performed after COVID-19 with persistent symptoms. (moderate recommendation for, consensus reached when strong and weak recommendations are merged)

Remarks for Question 7: Should CPET be routinely performed after COVID-19 with persistent symptoms? 23% (second survey: 14%) strong recommendation for, 42% (second survey: 68%) weak recommendation for, 5% (second survey: 9%) strong recommendation against, 16% (second survey: 9%) weak recommendation against, 14% (second survey: 0%) no recommendation.

Following the acute phase of COVID-19, approximately 1 out of 10 persons do not recover and may seek healthcare advice with a variety of symptoms such as a reduced exercise capacity, cough, thoracic pain, fatigue, and neuropsychological problems. Symptoms may overlap, affect any organ system and impact on quality of life. In the majority of patients, these symptoms resolve and rarely persist beyond 12 weeks after the acute phase. A recent US study found that only 65% of people had returned to their previous level of health 14–21 days after a positive test [52]. However, symptoms may persist for significantly longer, with fever, fatigue and breathlessness that may even recur in some individuals [11 , 25 , 53]. The LC syndrome refers to individuals with persistent symptoms extending beyond 4–12 weeks after the acute phase that are not explained by an alternative diagnosis [11 , 15]. These patients may need therapeutic advice with specialist investigation, rehabilitation, psychological support and further follow-up. To address these issues, post-COVID/LC assessment clinics have been established to support GPs after initial evaluation. An increasing number of LC clinics are being installed and specific guidelines have been formulated [15].

These clinics should ideally provide a multidisciplinary assessment by providing necessary resources for the care of patients recovering from COVID-19 [54]. Since the exact nature of the multiple deficits is unclear, one objective of such clinics is to ensure continuity of care and accurately track important health related outcomes. The multi-professional team comprises pulmonologists, rheumatologists, neurologists, psychiatrists, cardiologists, otolaryngologists, dermatologists, internal medicine physicians, nutritionists, physiotherapists, nephrologists, and others.

In general, the majority of the panel recognizes the importance of such clinics and several comments to the question highlight the importance of a multi-/interdisciplinary and multi-professional approach due to the wide range of symptoms. However, access may be limited for some patients where no such clinics exist in the vicinity. Since the benefit of such centers is not based on a body of evidence, tertiary centers should provide reasonable efforts to include patients in registries and clinical trials.

Patients with persistent symptoms after COVID-19 are recommended to have access to specialized multidisciplinary post-COVID-19 clinics or networks. (moderate recommendation for, consensus reached when strong and weak recommendations are merged)

Remarks for Question 8: Should patients with persistent symptoms after COVID-19 have access to specialized multidisciplinary post-COVID-19 clinics or networks? 65% (second survey: 55%) strong recommendation for, 28% (second survey: 41%) weak recommendation for, 0% (second survey: 0%) strong recommendation against, 2% (second survey: 0%) weak recommendation against, 5% (second survey: 5%) no recommendation.

Bronchiolitis and bronchial inflammation are common findings with many viral diseases, specifically in children [55]. Bronchiolitis leads to discrepancies between lung opacities and poor oxygenation while compliance is preserved [56]. On chest CT, small airways disease manifests by opacities with mosaic patterns [20 , 45]. The long-term outcome of these changes and the usefulness of corticosteroids remain unclear. Prior inhaled corticosteroid (ICS) use is not significantly associated with COVID-19 incidence in patients with either COPD or asthma or early clinical outcomes among patients with COVID-19 [57 , 58 , 59]. However, ICS may improve COVID-19-related bronchial syndromes, like for most other viral exacerbations in asthma or COPD [60].

The frequency of patients presenting with new-onset pulmonary obstructive disease after COVID-19 is unclear and not consistently addressed in the literature. Some patients might have undiagnosed underlying asthma or COPD. Nevertheless, some radiological findings suggest the presence of small airway disease. An empirical treatment trial may be performed on a case-by-case basis.

Patients after COVID-19 who present with new obstructive lung disease are recommended to be offered empiric topic inhaled or systemic steroid treatment. (moderate recommendation for, consensus reached when strong and weak recommendations are merged)

Remarks for Question 9: Should patients after COVID-19 who present with new onset obstructive lung disease have empiric topic inhaled or systemic steroid treatment? 33% (second survey: 36%) strong recommendation for, 37% (second survey: 36%) weak recommendation for, 5% (second survey: 5%) strong recommendation against, 5% (second survey: 9%) weak recommendation against, 21% (second survey: 14%) no recommendation.

Cough is among the most common symptoms associated with viral respiratory infections. 36–43% of people with a viral upper respiratory tract infection still have cough 3 months after the infection [61]. Cough is not the primary complaint occurring after COVID-19 but has been reported. In an Italian study, 60 days after initial symptom onset, only 16% of patients complained about persistent cough [10]. Similarly, in a study of formerly hospitalized UK patients, 12% of patients reported

cough 90 days after onset of initial symptoms [62]. However, in such individuals, cough is a common complaint leading to GP consultations, increased health costs, and an impaired quality of life. ICS reduce the numbers of inflammatory cells in the airways and downregulate multiple inflammatory genes encoding for cytokines, chemokines, inflammatory enzymes, and receptors [63]. Although the suppression of mucosal inflammation is associated with a clinically relevant reduction of bronchial hyperreactivity, the effect of inhaled steroids for other causes of cough remains controversial [64]. Moreover, recent guidelines differ in their recommendations of ICS for chronic cough management [65 , 66].

The role of ICS during the acute phase of COVID-19 is different. While preparing the current guidelines (between survey 1 and survey 2), an open-label RCT investigating inhaled budesonide given within 7 days of symptom onset was pre-published [67]. The likelihood of requiring urgent care, emergency department consultation and hospitalization was significantly reduced in adults inhaling budesonide, providing first evidence for an affordable and effective intervention. Additional studies are required to confirm these findings.

Methacholine testing to investigate chronic cough in patients after COVID-19 infection is rarely performed due to increased infectious risks in case of persistent viral replication. Other causes of chronic cough should be evaluated and treated if identified. The committee discussed an empiric therapy of ICS in cough following COVID-19 and recognizes that the evidence for inhaled steroids in non-COVID-19 post-viral cough is still low, with inconsistent recommendations formulated by the pulmonary societies. No clinical trials exist in persistent cough related to COVID-19. Since ICS are easy to apply with an acceptable safety profile, a limited trial of 4–6 weeks may be an option to treat cough after COVID-19. The change between survey 1 (strong recommendation for: 12%) and 2 (strong recommendation for: 32%) may have been caused by the recent pre-publication about ICS in acute COVID-19 infection [67] or personal experience. In patients with preexistent asthma or eosinophilic airway disease, ICS should be continued as the mainstay of therapy.

Patients after COVID-19 who present with persistent cough are recommended to have empiric inhaled topic steroids. (moderate recommendation for, consensus reached when strong and weak recommendations are merged)

Remarks for Question 10: Should patients after COVID-19 who present with persistent cough have empiric inhaled topic steroids? 12% (second survey: 32%) strong recommendation for, 49% (second survey: 45%) weak recommendation for, 5% (second survey: 5%) strong recommendation against, 12% (second survey: 9%) weak recommendation against, 23% (second survey: 9%) no recommendation.

Post-infectious inflammatory processes often include organizing pneumonia (OP) that may occur after COVID-19 infection [68 , 69 , 70 , 71]. OP generally improves with oral corticosteroids and recent observations suggest that patients with interstitial abnormalities after COVID-19 may benefit from systemic steroid trials [72]. This study showed that patients with symptomatic infiltrates at 6 weeks and significant persistent functional deficits improved with an average of 26 mg/day of prednisone with a dose-reduction scheme over 6 weeks. Such treatment was associated with a mean relative increase in transfer factor by 31.6% and FVC by 9.6%, as well as significant symptomatic and radiological improvement. This observational study was not randomized but showed a marked clinical improvement of these patients in less than 12 weeks overall, after a careful initial evaluation. Furthermore, this study raises the opportunity to treat OP related lesions after COVID-19 infections with low doses systemic steroids, potentially preventing persistent symptomatic interstitial lung disease [72].

The committee recognizes a steroid trial as a possible treatment approach if, e.g., OP or bronchiolitis can be diagnosed and acute infection has been ruled out. As no RCT is currently published, this remains a case-by-case decision, which should be considered especially if lung function is impaired and the patient remains symptomatic.

Patients after COVID-19 who present with interstitial abnormalities after exclusion of an active infection are recommended to be evaluated to receive an empiric systemic steroid trial. (moderate recommendation for, consensus reached when strong and weak recommendations are merged)

Remarks for Question 11: Should patients after COVID-19 who present with interstitial abnormalities after exclusion of an active infection receive an empiric systemic steroid trial? 16% (second survey: 14%) strong recommendation for, 40% (second survey: 59%) weak recommendation for, 5% (second survey: 9%) strong recommendation against, 26% (second survey: 5%) weak recommendation against, 14% (second survey: 14%) no recommendation.

Recent evidence showed that antifibrotic drugs are well tolerated and provide a benefit in progressive fibrosing lung disease independently of the underlying pathology [73 , 74]. Pulmonary fibrosis is a complication that occurs after COVID-19 [75]. Mechanisms of disease may overlap between both type of disorders, including susceptibility in men and increased age, as well as cellular mechanisms (e.g., ACE2 involvement) [76]. This complication of COVID-19 has raised concern within the pulmonary community, although the precise frequency of complicating fibrotic lung disease is unknown with currently only case series that exist. Recent publications suggest that antifibrotic drugs may be beneficial in patients with fibrosis after COVID-19 [37 , 76 , 77]. Although RCTs are still lacking, several studies with nintedanib (NCT04619680 , NCT04541680 , NCT04338802) and pirfenidone (NCT04607928 , NCT04653831) are currently ongoing.

The committee agreed that evidence from ongoing RCT should be awaited to evaluate effects of antifibrotic drugs in COVID-19-induced fibrosis. According to the committees' personal experience, fibrosis after COVID-19 is usually nonprogressive. Antifibrotic treatment may be indicated if underlying progressive ILD (i.e., IPF) has been fortuitously discovered. Otherwise, patients should be evaluated on a case-by-case basis for compassionate use.

It is unclear whether patients after COVID-19 who present with signs of pulmonary fibrosis should receive specific antifibrotic drugs. (suggestion for no recommendation, no consensus)

Remarks for Question 12: Should patients after COVID-19 who present with signs of pulmonary fibrosis receive specific antifibrotic drugs? 9% (second survey: 5%) strong recommendation for, 28% (second survey: 32%) weak recommendation for, 7% (second survey: 0%) strong recommendation against, 16% (second survey: 9%) weak recommendation against, 40% (second survey: 55%) no recommendation.

Current evidence for rehabilitation after COVID-19 is weak but steadily increasing [78]. Clinical trials are ongoing to evaluate the effects of pulmonary rehabilitation after COVID-19 [11]. Interim guidance from the European Respiratory Society has already recommended post-COVID-19 rehabilitation [19]. Similarly, the German S3 Recommendations propose post-COVID-19 rehabilitation [27].

The committee strongly supports the panel decision to recommend pulmonary rehabilitation in patients with ongoing respiratory symptoms.

Patients after COVID-19 who present with persistent respiratory symptoms are recommended to undergo a rehabilitation program. (strong recommendation for, consensus reached)

Remarks for Question 13: Should patients after COVID-19 who present with persistent respiratory symptoms undergo a rehabilitation program? 86% (second survey: 91%) strong recommendation for, 7% (second survey: 5%) weak recommendation for, 0% (second survey: 0%) strong recommendation against, 0% (second survey: 5%) weak recommendation against, 7% (second survey: 0%) no recommendation.

Despite the lack of a clear definition of LC, persisting respiratory symptoms and pulmonary function impairment more than 1 month after COVID-19 may indicate LC syndrome. A broadly supported, pragmatic, and clear definition is required to standardize research and support future therapeutic strategies. Moreover, evidence for the management and treatment of pulmonary manifestations of LC is still lacking. The European Respiratory Society provided initial interim guidance on rehabilitation [19], but many aspects of disease management and specific treatment approaches remain unclear to date for practitioners. Clinical trials to address several of the questions raised by the committee are currently ongoing [11]. While awaiting additional evidence, we herein provide interim guidance for patient care based on the experience of pulmonologists from Switzerland and the results of our survey-based consensus.

Physicians are facing patients with symptoms and functional impairment that need to be addressed. These consensus-based recommendations provide an interim support for practitioners awaiting results from ongoing and future trials. The recommendations need to be carefully reconsidered and revised as new knowledge emerges about pulmonary LC.

This work does not involve human subjects and informed consent was not required. No ethical approval was necessary for this survey.

M.F.C. has received unrestricted grants and/or speaker fees from Boehringer Ingelheim, Roche and Novartis unrelated to this work. C.F.C. has received payments for lectures/speaking, development of educational materials, and travel/accommodation/meeting expenses/ advisory boards from Roche, Novartis, Boehringer, GSK, Astra Zeneca, Sanofi, Vifor, OM Pharma, and Mundipharma. C.v.G. has received honoraria for consulting, advisory role, or lectures from AstraZeneca, Boehringer Ingelheim, GSK, Mundipharma, Novartis, OM Pharma, Pfizer, PneumRx, and Pulmonx Sanofi. The other authors have no conflicts of interest to declare in relation to this work.

M.F.C., P.O.B., C.F.C., P.M.S., L.N., and C.v.G. drafted the questions for the Delphi survey during a virtual meeting before sending them to the participants, M.F.C. collected and evaluated the survey results. M.F.C., P.O.B., C.F.C., P.M.S., L.N., and C.v.G. drafted the first version of the manuscript, discussed the results during a virtual meeting, finalized the manuscript, and approved the last version.

Swiss COVID Lung Study Group, on behalf of SGP/SSP.

Dan Adler, Andrea Azzola, Otto Brändli, Martin Brutsche, Gregory Clark, Christian Clarenbach, Patrick Fachinger, Gregoire Gex, Peter Grendelmeier, Ivan Guerreiro, Rene Hage, Raphael Heinzer, Markus Hofer, Katrin Hostettler, Jean-Paul Janssens, Werner Karrer, Rebekka Kleiner, Philipp Latzin, Irene Laube, Marco Laures, Romain Lazor, Daniele Marino, Geneviève Nicolet, Adam Ogna, Nikolay Pavlov, Alexander Pavlovic, Jerome Plojoux, Susanne Pohle, Maura Prella, Jochen Rüdiger, Otto Schoch, Dieter Scholtze, Macé Schuurmans, Thomas Sigrist, Alina Stadler, Claudia Steurer, Robert Thurnheer, Alexander Turk.

Tsui PT Kwok ML Yuen H Lai ST Severe acute respiratory syndrome: clinical outcome and prognostic correlates *Emerg Infect Dis* 2003 9 9 (9) 1064 9 14519241 10.3201/eid0909.030362 PMC3016795 2 de Wit E van Doremalen N Falzarano D Munster VJ SARS and MERS: recent insights into emerging coronaviruses *Nat Rev Microbiol* 2016 8 14 (8) 523 34 27344959 10.1038/nrmicro.2016.81 PMC7097822 3 Hui DS Wong KT Ko FW Tam LS Chan DP Woo J The 1-year impact of severe acute respiratory syndrome on pulmonary function, exercise capacity, and quality of life in a cohort of survivors *Chest* 2005 10 128 (4) 2247 61 16236881 10.1378/chest.128.4.2247 PMC7094276 4 Ngai JC Ko FW Ng SS To KW Tong M Hui DS The long-term impact of severe acute respiratory syndrome on pulmonary function, exercise capacity and health status *Respirology* 2010 4 15 (3) 543 50 20337995 10.1111/j.1440-1843.2010.01720.x PMC7192220 5 Huang C Wang Y Li X Ren L Zhao J Hu Y Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China *Lancet* 2020 2 395 (10223) 497 506 31986264

10.1016/S0140-6736(20)30183-5 PMC7159299 6 Torres Acosta MA Singer BD Pathogenesis of COVID-19-induced ARDS: implications for an ageing population *Eur Respir J* 2020 9 56 (3) 2002049 32747391 10.1183/13993003.02049-2020 PMC7397945 7 Herridge MS Tansey CM Matté A Tomlinson G Diaz-Granados N Cooper A Canadian Critical Care Trials Group Functional disability 5 years after acute respiratory distress syndrome *N Engl J Med* 2011 4 364 (14) 1293 304 21470008 10.1056/NEJMoa1011802 8 Peter G Gibson, Ling Qin SHP. COVID-19 acute respiratory distress syndrome (ARDS): clinical features and differences from typical pre-COVID-19 ARDS *Med J Aust* 2020 7 213 (2) 10.5694/mja2.50674 PMC7361309 32572965 9 Berlin DA Gulick RM Martinez FJ Severe Covid-19 *N Engl J Med* 2020 12 383 (25) 2451 60 32412710 10.1056/NEJMcp2009575 10 Carfi A Bernabei R Landi F Gemelli Against COVID-19 Post-Acute Care Study Group Persistent symptoms in patients after acute COVID-19. *JAMA - JAMA* 2020 8 324 (6) 603 5 32644129 10.1001/jama.2020.12603 PMC7349096 11 Nalbandian A Sehgal K Gupta A Post-acute COVID-19 syndrome *Nat Med* 2021 10.1038/s41591-021-01283-z PMC8893149 33753937 12 Greenhalgh T Knight M A'Court C Buxton M Husain L Management of post-acute covid-19 in primary care *BMJ* 2020 8 370 m3026 32784198 10.1136/bmj.m3026 13 Amenta EM Spallone A Rodriguez-Barradas MC El Sahly HM Atmar RL Kulkarni PA Postacute covid-19: an overview and approach to classification *Open Forum Infect Dis* 2020 10 7 (12) a509 10.1093/ofid/ofaa509 PMC7665635 33403218 14 Brodin P Immune determinants of COVID-19 disease presentation and severity *Nat Med* 2021 1 27 (1) 28 33 33442016 10.1038/s41591-020-01202-8 15 National Institute for Health and Care Excellence Practitioners RC of G, Scotland HI COVID-19 rapid guideline: managing the long-term effects of COVID-19 *NICE Guidel* 2020 33555768 16 Ackermann M Verleden SE Kuehnel M Haverich A Welte T Laenger F Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19 *N Engl J Med* 2020 7 383 (2) 120 8 32437596 10.1056/NEJMoa2015432 PMC7412750 17 Brigham E O'Toole J Kim SY Friedman M Daly L Kaplin A The Johns Hopkins Post-Acute COVID-19 Team (PACT): A Multidisciplinary, Collaborative, Ambulatory Framework Supporting COVID-19 Survivors *Am J Med* 2021 4 134 (4) 462 467.e1 33444589 10.1016/j.amjmed.2020.12.009 PMC7801819 18 Gorna R MacDermott N Rayner C Long COVID guidelines need to reflect lived experience *Lancet* 2020 10.1016/S0140-6736(20)32705-7 PMC7755576 33357467 19 Spruit MA Holland AE Singh SJ Tonia T Wilson KC Troosters T COVID-19: Interim Guidance on Rehabilitation in the Hospital and Post-Hospital Phase from a European Respiratory Society and American Thoracic Society-coordinated International Task Force *Eur Respir J* 2020 8 56 (6) 2002197 10.1183/13993003.02197-2020 PMC7427118 32817258 20 Guler SA Ebner L Aubry-Beigelman C Bridevaux PO Brutsche M Clarenbach C Pulmonary function and radiological features 4 months after COVID-19: first results from the national prospective observational Swiss COVID-19 lung study *Eur Respir J* 2021 4 57 (4) 2003690 33419891 10.1183/13993003.03690-2020 PMC8082329 21 Wilson KC Consensus-based recommendations in respiratory medicine *Eur Respir J* 2020 56 (6) 200288 22 Garrigues E Janvier P Kherabi Y Le Bot A Hamon A Gouze H Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19 *J Infect* 2020 12 81 (6) e4 6 32853602 10.1016/j.jinf.2020.08.029 PMC7445491 23 Lerum TV Aaløkken TM Brønstad E Dyspnoea, lung function and CT findings three months after hospital admission for COVID-19 *Eur Respir J* 2020 10.1183/13993003.03448-2020 PMC7736755 33303540 24 Sonnweber T Sahanic S Pizzini A Cardiopulmonary recovery after COVID-19 – an observational prospective multi-center trial *Eur Respir J* 2020 10.1183/13993003.03481-2020 PMC7736754 33303539 25 Huang C Huang L Wang Y Li X Ren L Gu X 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study *Lancet* 2021 1 397 (10270) 220 32 33428867 10.1016/S0140-6736(20)32656-8 PMC7833295 26 George PM Barratt SL Condliffe R Desai SR Devaraj A Forrest I Respiratory follow-up of patients with COVID-19 pneumonia *Thorax* 2020 11 75 (11) 1009 16 32839287 10.1136/thoraxjnl-2020-215314 27 Kluge Stefan Janssens Uwe Welte Tobias Weber-Carstens Steffen Schälte Gereon Spinner Christoph D. Malin Jakob J. Gastmeier Petra Langer Florian Wepler Martin Westhoff Michael Pfeifer Michael Rabe Klaus F. Hoffmann Florian Böttiger Bernd W. CK. S3-Leitlinie - Empfehlungen zur stationären Therapie von Patienten mit COVID-19 AWMF online 2021 10.1055/a-1334-1925 33450783 28 Trinkmann F Müller M Reif A Kahn N Kreuter M Trudzinski F Lung Network Rhine-Neckar-Region Residual symptoms and lower lung function in patients recovering from SARS-CoV-2 infection *Eur Respir J* 2021 2 57 (2) 2003002 33479105 10.1183/13993003.03002-2020 PMC7821834 29 Mo X Jian W Su Z Chen M Peng H Peng P Abnormal pulmonary function in COVID-19 patients at time of hospital discharge *Eur Respir*

J 2020 6 55 (6) 2001217 32381497 10.1183/13993003.01217-2020 PMC7236826 30 Park WB Jun KI Kim G Choi JP Rhee JY Cheon S Correlation between pneumonia severity and pulmonary complications in Middle East respiratory syndrome J Korean Med Sci 2018 5 33 (24) e169 29892209 10.3346/jkms.2018.33.e169 PMC5990444 31 Graham BL Steenbruggen I Miller MR Barjaktarevic IZ Cooper BG Hall GL Standardization of spirometry 2019 update an official American Thoracic Society and European Respiratory Society technical statement Am J Respir Crit Care Med 2019 10 200 (8) e70 88 31613151 10.1164/rccm.201908-1590ST PMC6794117 32 Frija-Masson J Debray MP Gilbert M Lescure FX Travert F Borie R Functional characteristics of patients with SARS-CoV-2 pneumonia at 30 days post-infection Eur Respir J 2020 8 56 (2) 2001754 32554533 10.1183/13993003.01754-2020 PMC7301832 33 Nusair S Abnormal carbon monoxide diffusion capacity in COVID-19 patients at time of hospital discharge Eur Respir J 2020 7 56 (1) 2001832 32703822 10.1183/13993003.01832-2020 PMC7376285 34 Chen R Gao Y Chen M Jian W Lei C Zheng J Impaired pulmonary function in discharged patients with COVID-19: more work ahead Eur Respir J 2020 7 56 (1) 2002194 32586883 10.1183/13993003.02194-2020 PMC7315814 35 Chapman DG Badal T King GG Thamrin C Caution in interpretation of abnormal carbon monoxide diffusion capacity in COVID-19 patients Eur Respir J 2021 1 57 (1) 2003263 33154026 10.1183/13993003.03263-2020 PMC7651835 36 George PM Wells AU Jenkins RG Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy Lancet Respir Med 2020 8 8 (8) 807 15 32422178 10.1016/S2213-2600(20)30225-3 PMC7228727 37 Townsend L Dowds J O'Brien K Sheill G Dyer AH O'Kelly B Persistent Poor Health Post-COVID-19 Is Not Associated with Respiratory Complications or Initial Disease Severity Ann Am Thorac Soc 2021 1 1 AnnalsATS 202009 1175OC 10.1513/AnnalsATS.202009-1175OC PMC8456724 33413026 38 Karen B Jacobson, Mallika Rao, Hector Bonilla, Aruna Subramanian, Isabelle Hack, Martina Madrigal, Upinder Singh, Prasanna Jagannathan PG. Patients with uncomplicated COVID-19 have long-term persistent symptoms and functional impairment similar to patients with severe COVID-19: a cautionary tale during a global pandemic Clin Infect Dis 2021 2 10.1093/cid/ciab103 PMC7929039 33624010 39 Crapo RO Casaburi R Coates AL ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories ATS statement: guidelines for the six-minute walk test Am J Respir Crit Care Med 2002 7 166 (1) 111 7 12091180 10.1164/ajrccm.166.1.at1102 40 Houchen-Wolloff L Daynes E Watt A Chaplin E Gardiner N Singh S Which functional outcome measures can we use as a surrogate for exercise capacity during remote cardiopulmonary rehabilitation assessments? A rapid narrative review ERJ Open Res 2020 12 6 (4) 00526-2020 33313302 10.1183/23120541.00526-2020 PMC7720684 41 Fuglebjerg NJ Jensen TO Hoyer N Rysø CK Lindegaard B Harboe ZB Silent hypoxia in patients with SARS CoV-2 infection before hospital discharge Int J Infect Dis 2020 10 99 100 1 32663601 10.1016/j.ijid.2020.07.014 PMC7836996 42 Daher A Balfanz P Cornelissen C Müller A Bergs I Marx N Follow up of patients with severe coronavirus disease 2019 (COVID-19): pulmonary and extrapulmonary disease sequelae Respir Med 2020 Nov-Dec 174 106197 33120193 10.1016/j.rmed.2020.106197 PMC7573668 43 Curci C Negrini F Ferrillo M Bergonzi R Bonacci E Camozzi DM Functional outcome after inpatient rehabilitation in post-intensive care unit COVID-19 patients: findings and clinical implications from a real-practice retrospective study Eur J Phys Rehabil Med 2021 1 10.23736/S1973-9087.20.06660-5 33393278 44 Curci C Pisano F Bonacci E Camozzi DM Ceravolo C Bergonzi R Early rehabilitation in post-acute COVID-19 patients: data from an Italian COVID-19 Rehabilitation Unit and proposal of a treatment protocol Eur J Phys Rehabil Med 2020 10 56 (5) 633 41 32667150 10.23736/S1973-9087.20.06339-X 45 Ebner L Funke-Chambour M von Garnier C Ferretti G Ghaye B Beigelman-Aubry C Imaging in the aftermath of COVID-19: what to expect Eur Radiol 2020 10.1007/s00330-020-07465-6 PMC7769564 33372242 46 van den Borst B Peters JB Brink M Schoon Y Bleeker-Rovers CP Schers H Comprehensive health assessment three months after recovery from acute COVID-19 Clin Infect Dis 2020 11 4 ciae1750 10.1093/cid/ciae1750 PMC7717214 33220049 47 Han X Fan Y Alwalid O Li N Jia X Yuan M Six-month Follow-up Chest CT Findings after Severe COVID-19 Pneumonia Radiology 2021 4 299 (1) E177 86 33497317 10.1148/radiol.2021203153 PMC7841877 48 Murphy JM Schnyder P Verschakelen J Leuenberger P Flower CD Linear opacities on HRCT in bronchiolitis obliterans organising pneumonia Eur Radiol 1999 9 (9) 1813 7 10602956 10.1007/s003300050928 49 Belli S Balbi B Prince I Cattaneo D Masocco F Zaccaria S Low physical functioning and impaired performance of activities of daily life in COVID-19 patients who survived hospitalisation Eur Respir J 2020 10 56 (4) 2002096 32764112 10.1183/13993003.02096-2020 PMC7411272 50 Gao Y Chen

R Geng Q Mo X Zhan C Jian W Cardiopulmonary exercise testing might be helpful for interpretation of impaired pulmonary function in recovered COVID-19 patients *Eur Respir J* 2021 1 57 (1) 2004265 33361097 10.1183/13993003.04265-2020 PMC7758779 51 Mohr A Dannerbeck L Lange TJ Pfeifer M Blaas S Salzberger B Cardiopulmonary exercise pattern in patients with persistent dyspnoea after recovery from COVID-19 *Multidiscip Respir Med* 2021 1 16 (1) 732 33623700 10.4081/mrm.2021.732 PMC7893311 52 Tenforde MW Kim SS Lindsell CJ Billig Rose E Shapiro NI Files DC IVY Network Investigators CDC COVID-19 Response Team IVY Network Investigators Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network - United States, March-June 2020 *MMWR Morb Mortal Wkly Rep* 2020 7 69 (30) 993 8 32730238 10.15585/mmwr.mm6930e1 PMC7392393 53 Rovere Querini P De Lorenzo R Conte C Brioni E Lanzani C Yacoub MR Post-COVID-19 follow-up clinic: depicting chronicity of a new disease *Acta Biomed* 2020 7 91 9-S 22 8 32701913 10.23750/abm.v91i9-S.10146 PMC8023087 54 National guidance for post-COVID syndrome assessment clinics. <https://www.england.nhs.uk/coronavirus/wp-content/uploads/sites/52/2020/11/C0840-national-guidance-for-post-covid-syndrome-assesment-clinics-111220.pdf> 55 Tripathi S Al-Sayyed B Gladfelter TR Comparative epidemiology, hospital course, and outcomes of viral respiratory infections in hospitalized pediatric patients *Indian J Med Microbiol* 2020 10.1016/j.ijmmb.2020.10.011 33610252 56 Huang CF Sun PT Tay CK Bronchiolitis and potential pathophysiological implications in coronavirus disease 2019 acute respiratory distress syndrome patients with near-normal respiratory compliance *Crit Care Med* 2020 10 48 (10) e993 4 32541570 10.1097/CCM.0000000000004470 PMC7314321 57 Choi JC Jung SY Yoon UA You SH Kim MS Baek MS Inhaled Corticosteroids and COVID-19 Risk and Mortality: A Nationwide Cohort Study *J Clin Med* 2020 10 9 (11) E3406 33114246 10.3390/jcm9113406 PMC7690894 58 Avdeev S Moiseev S Brovko M Low prevalence of bronchial asthma and chronic obstructive lung disease among intensive care unit patients with COVID-19 2020 *Allergy Eur J Allergy Clin Immunol* 10.1111/all.14420 PMC7283669 32455491 59 Li X Xu S Yu M Wang K Tao Y Zhou Y Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan *J Allergy Clin Immunol* 2020 7 146 (1) 110 8 32294485 10.1016/j.jaci.2020.04.006 PMC7152876 60 Lipworth B Chan R Kuo CR Use of inhaled corticosteroids in asthma and coronavirus disease 2019: keep calm and carry on *Ann Allergy Asthma Immunol* 2020 11 125 (5) 503 4 32585180 10.1016/j.anai.2020.06.026 PMC7329280 61 Ryan NM Vertigan AE Ferguson J Wark P Gibson PG Clinical and physiological features of postinfectious chronic cough associated with H1N1 infection *Respir Med* 2012 1 106 (1) 138 44 22056406 10.1016/j.rmed.2011.10.007 62 Arnold DT Hamilton FW Milne A Morley AJ Viner J Attwood M Patient outcomes after hospitalisation with COVID-19 and implications for follow-up: results from a prospective UK cohort *Thorax* 2020 Dec 3 76 (4) 399 401 33273026 10.1136/thoraxjnl-2020-216086 PMC7716340 63 Barnes PJ How corticosteroids control inflammation: Quintiles Prize Lecture 2005 *Br J Pharmacol* 2006 6 148 (3) 245 54 16604091 10.1038/sj.bjp.0706736 PMC1751559 64 Juniper EF Kline PA Vanzieleghem MA Ramsdale EH O'Byrne PM Hargreave FE Long-term effects of budesonide on airway responsiveness and clinical asthma severity in inhaled steroid-dependent asthmatics *Eur Respir J* 1990 11 3 (10) 1122 7 2090474 65 Gibson P Wang G McGarvey L Vertigan AE Altman KW Birring SS CHEST Expert Cough Panel Treatment of unexplained chronic cough chest guideline and expert panel report *Chest* 2016 1 149 (1) 27 44 26426314 10.1378/chest.15-1496 PMC5831652 66 Morice AH Millqvist E Bieksiene K Birring SS Dicipinigitis P Domingo Ribas C ERS guidelines on the diagnosis and treatment of chronic cough in adults and children *Eur Respir J* 2020 1 55 (1) 1901136 31515408 10.1183/13993003.01136-2019 PMC6942543 67 Ramakrishnan S Nicolau DV Langford B Inhaled Budesonide in the Treatment of Early COVID-19 Illness: A Randomised Controlled Trial. *SSRN Electron J* 2021 10.1016/S2213-2600(21)00160-0 PMC8040526 33844996 68 Kory P Kanne JP SARS-CoV-2 organising pneumonia: 'Has there been a widespread failure to identify and treat this prevalent condition in COVID-19?' *BMJ Open Respir Res* 2020 9 7 (1) e000724 10.1136/bmjresp-2020-000724 PMC7509945 32963028 69 Vadász I Husain-Syed F Dorfmueller P Roller FC Tello K Hecker M Severe organising pneumonia following COVID-19 *Thorax* 2020 Nov 11 horaxjnl-2020-216088 10.1136/thoraxjnl-2020-216088 33177230 70 Wang Y Jin C Wu CC Zhao H Liang T Liu Z Organizing pneumonia of COVID-19: time-dependent evolution and outcome in CT findings *PLoS One* 2020 11 15 (11) e0240347 33175876 10.1371/journal.pone.0240347 PMC7657520 71 Horii H Kamada K Nakakubo S Yamashita Y Nakamura J Nasuhara Y Rapidly progressive organizing pneumonia associated with COVID-19 *Respir Med Case Rep* 2020 31

101295 33224726 10.1016/j.rmcr.2020.101295 PMC7671928 72 Myall KJ Mukherjee B Castanheira AM Lam JL Benedetti G Mak SM Persistent Post-COVID-19 Interstitial Lung Disease. An Observational Study of Corticosteroid Treatment Ann Am Thorac Soc 2021 5 18 (5) 799 806 33433263 10.1513/AnnalsATS.202008-1002OC PMC8086530 73 Flaherty KR Wells AU Cottin V Devaraj A Walsh SL Inoue Y INBUILD Trial Investigators Nintedanib in progressive fibrosing interstitial lung diseases N Engl J Med 2019 10 381 (18) 1718 27 31566307 10.1056/NEJMoa1908681 74 Maher TM Corte TJ Fischer A Kreuter M Lederer DJ Molina-Molina M Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial Lancet Respir Med 2020 2 8 (2) 147 57 31578169 10.1016/S2213-2600(19)30341-8 75 Picchi G Mari A Ricciardi A Carucci AC Sinatti G Cosimini B Three cases of covid-19 pneumonia in female patients in Italy who had pulmonary fibrosis on follow-up lung computed tomography imaging Am J Case Rep 2020 11 21 e926921 33219200 10.12659/AJCR.926921 PMC7690330 76 Lechowicz K Drożdżal S Machaj F Rosik J Szostak B Zegan-Barańska M COVID-19: The Potential Treatment of Pulmonary Fibrosis Associated with SARS-CoV-2 Infection J Clin Med 2020 6 9 (6) E1917 32575380 10.3390/jcm9061917 PMC7356800 77 Spagnolo P Balestro E Aliberti S Cocconcelli E Biondini D Casa GD Sverzellati N Maher T Pulmonary Fibrosis Secondary to COVID-19: A Call to Arms? Lancet Respir Med 2020 May 15 S2213-2600 (20) 30222 8 10.1016/S2213-2600(20)30222-8 PMC7228737 32422177 78 Negrini F De Sire A Andrenelli E Rehabilitation and COVID-19: a rapid living systematic review 2020 by Cochrane Rehabilitation Field. Update as of October 31st, 2020 Eur J Phys Rehabil Med 2020 10.23736/S1973-9087.20.06723-4 33263249 Table 1 Modified proposal for the definition of acute and long COVID [15]

Overview of the voting results for each question from both surveys